Cat. No.: HY-17015

Peramivir trihydrate

(Synonyms: RWJ 270201 trihydrate; BCX 1812 trihydrate)

13 Cited Publications

Customer Review

Based on 13 publication(s) in Google Scholar

Peramivir trihydrate (RWJ-270201 trihydrate) is a highly potent, selective and orally active influenza virus neuraminidase (NA) inhibitor, with IC₅₀ values ranging from 0.9 to 4.3 nM for nine NA subtypes.

For research use only. We do not sell to patients.

Purity: 98.30%
CAS No.: 1041434-82-5
Formula: C₁₅H₃₄N₄O₇
Molecular Weight:382.45

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Peramivir trihydrate Chemical Structure

CAS No.: 1041434-82-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (13)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

IC50：0.9-4.3 nM (NA)^[2]

All IKK Isoforms :

All JNK Isoforms :

All STAT Isoforms :

All p38 MAPK Isoforms :

All ERK Isoforms :

In Vitro

Peramivir trihydrate (0.3125-40 μM, 4 h) has nontoxicity to macrophage^[1].
Peramivir trihydrate (2-10 μM, 6-12 h) inhibits cytokine release in LPS-induced hPBMCs^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

RAW 264.7
Concentration:

0.3125 μM, 0.625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM
Incubation Time:

4 h
Result:

Showed no apparent toxicity in the peramivir-treated macrophages at concentrations up to 40 μM.

In Vivo

Peramivir trihydrate (20-60 mg/kg, i.p., single dose) inhibits LPS-induced cytokine storm, attenuates acute lung injury and prolongs the survival in cytokine storm syndrome model mice^[1].
Peramivir trihydrate (75 mg/kg, i.m., once a day for 7 days) rescued BALB scid mice from lethal challenge with BR/08 in immunocompromised murine models of infuenza B virus infection^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Cytokine storm syndrome model mice^[1].
Dosage:

20 mg/kg, 60 mg/kg
Administration:

Intraperitoneal injection (i.p.)
Result:

Decreased 8 cytokines including TNF-a, IFN-a, IFN-γ, chemokines (MCP-1), GM-CSF, IL-1β, IL-6 and IL-12. Showed less inflammatory cell infiltrations, mild alveolar thickening and less bleeding points or congestion. Showed significant protective effects to the lung tissues.

Chemical Information

CAS No. 1041434-82-5
Appearance Solid
Molecular Weight 382.45
Formula C₁₅H₃₄N₄O₇
Color White to off-white
SMILES

O[C@H]1[C@]([C@H](C(CC)CC)NC(C)=O)([H])[C@H](NC(N)=N)C[C@@H]1C(O)=O.[H]O.[H]O.[H]O
Synonyms

RWJ 270201 trihydrate; BCX 1812 trihydrate
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (13)

All

Sort by:

Journal Impact Factor

Nat Commun

Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. [Abstract]

2013;4:2854. PMID: 24326875
NPJ Digit Med

Predictive modeling & mechanistic validation of synergistic pimodivir combinations for anti-influenza therapy via PB2cap affinity boost. [Abstract]

2025 Nov 21;8(1):712. PMID: 41272280
Emerg Microbes Infect

Efficient airborne transmission of influenza D virus in ferret models and serological evidence of human exposure in Northeast China. [Abstract]

2025 Dec;14(1):2564308. PMID: 41069204
Int Immunopharmacol

Lidocaine inhibits influenza a virus replication by up-regulating IFNα4 via TBK1-IRF7 and JNK-AP1 signaling pathways. [Abstract]

2023 Feb:115:109706. PMID: 36638664
PLoS Pathog

The HN protein of Newcastle disease virus induces cell apoptosis through the induction of lysosomal membrane permeabilization. [Abstract]

2024 Feb 14;20(2):e1011981. PMID: 38354122
Sci Rep

Substitution of I222L-E119V in neuraminidase from highly pathogenic avian influenza H7N9 virus exhibited synergistic resistance effect to oseltamivir in mice. [Abstract]

2021 Aug 11;11(1):16293. PMID: 34381119
Int J Infect Dis

Antiviral susceptibility of SARS-CoV-2 and influenza viruses from 3 co-infected pediatric patients. [Abstract]

2024 Jun 27:107134. PMID: 38944411
Antimicrob Agents Chemother

Development of Novel Anti-influenza Thiazolides with Relatively Broad-Spectrum Antiviral Potentials. [Abstract]

2020 Jun 23;64(7):e00222-20. PMID: 32312780
PLoS One

An easy, rapid, and sensitive method for detection of drug-resistant influenza virus by using a sialidase fluorescent imaging probe, BTP3-Neu5Ac. [Abstract]

2018 Jul 12;13(7):e0200761. PMID: 30001430
PLoS One

Detection of peramivir and laninamivir, new anti-influenza drugs, in sewage effluent and river waters in Japan. [Abstract]

2015 Jun 25;10(6):e0131412. PMID: 26110817
bioRxiv

Inhibiting Glycan Degradation Prevents HIV-Induced Inflammaging and Cognitive Impairment. [Abstract]

2025 Nov 17:2025.11.17.688839. PMID: 41332691
University of Glasgow

2023.
Chemosphere

Fate of new three anti-influenza drugs and one prodrug in the water environment. [Abstract]

2017 Feb:169:550-557. PMID: 27898328

Solvent & Solubility

In Vitro:

H₂O : 5 mg/mL (13.07 mM; Need ultrasonic)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6147 mL

13.0736 mL

26.1472 mL

5 mM

0.5229 mL

2.6147 mL

5.2294 mL

10 mM

0.2615 mL

1.3074 mL

2.6147 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 4.55 mg/mL (11.90 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (278 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang C, et al. Peramivir, an anti-influenza virus drug, exhibits potential anti-cytokine storm effects [J]. Frontiers in Immunology, 2022, 13: 856327. [Content Brief]

[2]. Pascua P N Q, et al. Pathogenicity and peramivir efficacy in immunocompromised murine models of influenza B virus infection [J]. Scientific reports, 2017, 7(1): 7345. [Content Brief]

[3]. Alame M M, et al.. Peramivir: a novel intravenous neuraminidase inhibitor for treatment of acute influenza infections [J]. Frontiers in microbiology, 2016, 7: 450. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O	1 mM	2.6147 mL	13.0736 mL	26.1472 mL	65.3680 mL
	5 mM	0.5229 mL	2.6147 mL	5.2294 mL	13.0736 mL
	10 mM	0.2615 mL	1.3074 mL	2.6147 mL	6.5368 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Peramivir trihydrate

13 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Peramivir trihydrate

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

MAPK Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Oxygen Sensing Compound Library

Anti-COVID-19 Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Glutamine Metabolism Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

EMA-Approved Drug Library

Pain-Related Compound Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Peramivir trihydrate

All IKK Isoforms

All JNK Isoforms

All STAT Isoforms

All p38 MAPK Isoforms

All ERK Isoforms

Biological Activity

Chemical Information

Publications (13)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Peramivir trihydrate Related Classifications

HY-17015 Related Classifications